News
Videos
Conferences
Events
Resources
Subscribe

|Videos|June 29, 2022

Future Perspectives in Renal Cell Carcinoma (RCC)

Author(s)Thomas Hutson, DO, PharmD

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.

Episodes in this series

EP. 1 Treatment Options for Patients with Renal Cell Carcinoma (RCC)

EP. 1 Treatment Options for Patients with Renal Cell Carcinoma (RCC)

EP. 2 Clinical Implications of the TIVO-3 Trial

EP. 2 Clinical Implications of the TIVO-3 Trial

EP. 3 Tivozanib: Adverse Event Profile and How Toxicities are Managed

EP. 4 Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

EP. 4 Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

EP. 5 Future Perspectives in Renal Cell Carcinoma (RCC)

EP. 5 Future Perspectives in Renal Cell Carcinoma (RCC)

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The U.S. FDA has issued an updated safety communication regarding two commonly used chemotherapy drugs, Xeloda and fluorouracil: © stock.adobe.com.

FDA Updates Safety Warnings for Common Chemotherapy Drugs

February 5th 2026

Image of Kidney

A Patients Navigation Guide to Stage 2 Clear Cell Renal Cell Carcinoma

February 1st 2026

Image of kidney.

What to Know About Your Stage 1 ccRCC Diagnosis

January 12th 2026

cancer diagnosis

Just Diagnosed with Cancer? Read This Before You Google Anything

ByChuck Stravin

January 9th 2026

kidney cancer

Understanding Your Stage 4 RCC Diagnosis: Insights on What to Expect

January 5th 2026

Trending on CURE

FDA Updates Safety Warnings for Common Chemotherapy Drugs

KTX-1001 Elicits Responses in Some With Multiple Myeloma

FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma

New Combination Treatment Approach Studied in Pancreatic Cancer

Biomarker-Free Relacorilant Combo Broadens Options in Ovarian Cancer